Oncology biopharmaceutical company Veru Inc. reported positive results for its COVID-19 drug candidate, with reduced deaths in hospitalized patients.
- Veru said the Independent Data Safety Monitoring Committee unanimously recommended that the Phase 3 clinical trial be terminated early given the efficacy and that no safety concerns were identified.
- The trial found that there was a 55% relative reduction in deaths compared with the placebo in moderate to severe hospitalized patients. The placebo group had a 45% mortality rate, and the sabizabulin-treated group had 20% mortality.
- Chief Executive Officer Mitchell Steiner said the study indicates that sabizabulin is the first drug to demonstrate a “clinically and statistically” meaningful reduction in deaths in hospitalized patients.
- Principal investigator Alan Skolnick said new variant infections and new challengers are expected in the short term as the country enters the fall and winter seasonal cycle.
The trial was conducted in the United States, Brazil, Colombia, Argentina, Mexico, and Bulgaria. VERU is up 39.74%.